Clinical Trials Logo

End Stage Renal Disease clinical trials

View clinical trials related to End Stage Renal Disease.

Filter by:

NCT ID: NCT03194321 Completed - Clinical trials for End Stage Renal Disease

Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

Start date: September 11, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate the safety of tacrolimus extended-release in HLA sensitized (HS, defined as panel reactive antibody ≥ 30%), kidney transplant recipients after desensitization with intravenous immunoglobulin (IVIG) and rituximab (also known as ritux) +/- plasma exchange (PLEX) per the standard of care with alemtuzumab induction.

NCT ID: NCT03189212 Completed - Clinical trials for End Stage Renal Disease

Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a telemedicine follow-up visit at the NYU Langone Transplant Institute is a feasible and acceptable alternative to a traditional in-center follow-up visit.

NCT ID: NCT03183245 Active, not recruiting - Clinical trials for End Stage Renal Disease

Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

Start date: September 29, 2017
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access

NCT ID: NCT03179072 Completed - Clinical trials for End Stage Renal Disease

Dehydr8 and Deactiv8

Start date: July 19, 2017
Phase:
Study type: Observational

Managing fluid status is a complex but fundamental part of the clinical care of people receiving haemodialysis (HD). Day-to-day fluid management is usually based on the concept of 'target weight' - the weight used to determine how much fluid should be removed during each dialysis session. However, the focus of this approach is usually on avoiding fluid overload (hypervolaemia), since this is associated with a higher incidence of cardiovascular and pulmonary events, in addition to increased morbidity and morbidity. As a consequence, a significant proportion of people on maintenance HD spend a great deal of time in a dehydrated state. Although dehydration is known to be associated with a number of unwanted consequences (e.g. headaches, severe fatigue, impaired cognitive and physiological function), there has been little research focusing on the impact dehydration has on the physical and psychosocial well-being of this patient group. Considering the short life expectancy of individuals with end-stage renal disease (ESRD) reliant on maintenance HD, particularly those who are unable to receive a renal transplant, we should be focused on improving their function and quality of life (QoL). Key issues that need addressing prior to developing interventions in this cohort are 1) investigating the best and alternative measures to assess hydration status and 2) documenting the biopsychosocial impact of typical target weight driven HD in a well-designed study.

NCT ID: NCT03171545 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

Enhancing the Cardiovascular Safety of Hemodialysis Care (Dialysafe)

Dialysafe
Start date: January 11, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is reduce episodes of intradialytic hypotension, low blood pressure during a hemodialysis session, in patients with End Stage Renal Disease (ESRD). Recruitment will take place on the clinic level rather than the patient level.

NCT ID: NCT03161197 Completed - Clinical trials for Chronic Kidney Diseases

Pain Relief Intervention of Meditation in Renal Disease (PRIMER)

PRIMER
Start date: April 24, 2015
Phase: N/A
Study type: Interventional

Kidney Disease subjects will be recruited to take part of a mindfulness-based stress reduction intervention for 8-10 sessions. All subjects will complete a baseline interview, one follow-up at 3 months and the close out interview at 5 months.

NCT ID: NCT03141983 Completed - Clinical trials for End-Stage Renal Disease

Anti-Cytokine Therapy for Hemodialysis InflammatION

ACTION
Start date: December 15, 2017
Phase: Phase 2
Study type: Interventional

Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION) is a phase II multi-center study to evaluate the safety and tolerability of anakinra, an IL-1 receptor antagonist, for patients treated with maintenance hemodialysis.

NCT ID: NCT03138564 Active, not recruiting - Clinical trials for End Stage Renal Disease

An Effectiveness-Implementation Trial of SPIRIT in ESRD

Start date: February 15, 2018
Phase: N/A
Study type: Interventional

Despite advances in dialysis, only 50% of dialysis patients are alive 3 years after the onset of end-stage renal disease (ESRD). Although withdrawal of dialysis precedes 1 in 4 deaths of patients with ESRD, withdrawal from dialysis and aggressive treatment is rarely discussed by patients and their surrogates with sufficient time to consider alternatives such as hospice or dying at home. Over the last decade, the researchers have developed and iteratively tested a patient and family-centered advance care planning intervention based on the Representational Approach to Patient Education called "Sharing Patient's Illness Representation to Increase Trust" (SPIRIT). SPIRIT is a 6-step, 2-session, face-to-face intervention to promote cognitive and emotional preparation for end-of-life decision making for patients with ESRD and their surrogates. This study is a multicenter, clinic-level cluster randomized trial to evaluate the effectiveness of SPIRIT delivered by dialysis care providers as part of routine care in free-standing outpatient dialysis clinics compared to usual care plus delayed SPIRIT implementation. The researchers will recruit 400 dyads of patients at high risk of death in the next year and their surrogates from dialysis clinics in four states. Patients and surrogates will complete questionnaires at baseline and two weeks after the intervention. Surrogates will complete a post-bereavement assessment three months after the death of the patient.

NCT ID: NCT03125265 Completed - Clinical trials for End Stage Renal Disease

DIETary Intake, Death and Hospitalization in Adult With End-stage Kidney Disease Treated With HemoDialysis (DIET-HD) Study

Start date: January 5, 2014
Phase: N/A
Study type: Observational

The DIETary intake, death and hospitalisation in adults with end-stage kidney disease treated with HaemoDialysis (DIET-HD) study is a multinational prospective cohort study designed to evaluate the association between nutrition and dietary patterns and health outcomes in prevalent adult haemodialysis patients in Europe and South America.

NCT ID: NCT03120611 Completed - Clinical trials for End Stage Renal Disease

Virtual Reality Versus Conventional Exercise Intradialysis

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

All participants exercised during 16 weeks following a conventional intradialysis exercise program. The last 4 weeks of the study participants were randomized into two different exercise programs intradialysis. One group exercised through a virtual reality exercise adapted specially for patients while receiving hemodialysis treatment. The other group exercised with a conventional exercise program, combining aerobic cycling and strengthening exercises.